Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Guardant Health (Nasdaq: GH) has launched two innovative tests for late-stage cancer management: the Guardant360 Response and Guardant360 TissueNext. The Guardant360 Response is a blood-only test that detects changes in circulating tumor DNA (ctDNA), providing early treatment response indicators up to eight weeks prior to traditional methods. The Guardant360 TissueNext offers tissue testing to complement the blood test, ensuring comprehensive patient evaluation. These additions enhance the Guardant360 portfolio, aiming to optimize treatment selection and improve clinical outcomes.
Guardant Health, Inc. (Nasdaq: GH) has appointed Chris Freeman as the Chief Commercial Officer for its oncology business, effective June 8, 2021. Freeman brings extensive experience in managing pharmaceutical brands, which will aid in the company's efforts to expand its oncology portfolio for advanced and early-stage cancers. CEO Helmy Eltoukhy emphasized Freeman's role in developing commercial strategies to enhance growth across various market segments.
Guardant Health reveals promising early results from the LUNAR-2 blood test at the 2021 ASCO Annual Meeting, demonstrating a 91% sensitivity for detecting early-stage colorectal cancer (CRC) with a specificity of 94%. With only 68% of adults over 50 screened for CRC, this test may improve compliance with CDC goals. The ECLIPSE trial, a 10,000-patient study, is underway to validate these findings and support FDA approval. Guardant's CEO emphasizes the test's effectiveness in both asymptomatic and symptomatic patients, showcasing its potential for clinical adoption in average-risk populations.
Guardant Health announces FDA approval for its Guardant360 CDx test, the first liquid biopsy companion diagnostic for KRAS G12C mutation profiling in patients with non-small cell lung cancer (NSCLC). This approval, based on CodeBreaK 100 trial data, identifies patients eligible for LUMAKRAS™ (sotorasib), a targeted therapy for KRAS G12C mutation. Lung cancer is the leading cancer death cause in the U.S., and this development enhances personalized treatment options significantly.
Guardant Health, Inc. (Nasdaq: GH) has filed a lawsuit against Natera, Inc. for false advertising and unfair competition related to misleading claims about Guardant's new oncology test, Guardant Reveal™. The lawsuit seeks to prevent Natera from disseminating false information and demands corrective actions. Guardant Reveal™ is a groundbreaking blood-only liquid biopsy test designed to help early-stage colorectal cancer survivors detect residual disease and recurrences. This legal action arises from allegations that Natera misrepresents the test's efficacy, impacting patient treatment opportunities.
Guardant Health announces FDA approval for the Guardant360®CDx liquid biopsy test, the first companion diagnostic for Janssen Biotech’s RYBREVANT™. Designed for tumor mutation profiling in non-small cell lung cancer (NSCLC), it identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted therapy after chemotherapy. With lung cancer being the leading cause of cancer death, this approval marks a significant advancement in treatment options. The Guardant360 CDx test offers rapid genomic results from a blood draw, enhancing oncologists' ability to personalize treatment for patients.
Guardant Health, a leader in precision oncology, will participate virtually in two upcoming investor conferences. The first is the William Blair 41st Annual Growth Stock Conference on June 1, featuring a fireside chat at 12:00 PM PT. The second is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, also at 12:00 PM PT.
Interested investors can access live and archived webcasts of these events via the company’s website. Guardant Health is known for its innovative blood tests and data analytics aimed at improving cancer care and patient outcomes.
Guardant Health (Nasdaq: GH) presented data at the 2021 ASCO Annual Meeting showcasing advancements in precision oncology through its blood tests. With 20 abstracts, the data emphasized the efficacy of blood-based genomic profiling in early-stage cancer screening and treatment monitoring. Key findings included a 91% sensitivity for early-stage colorectal cancer detection via the LUNAR-2 test and high predictive value of the Guardant Reveal test in detecting minimal residual disease. These innovations aim to enhance treatment decisions and patient outcomes in cancer care.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
What does Guardant Health, Inc. specialize in?
What are the main products offered by Guardant Health?
What is Guardant360 CDx?
How does Guardant Health support cancer research?
What is the significance of the Reveal test?
What is the purpose of the Shield test?
Who are some of the major investors in Guardant Health?
Where is Guardant Health, Inc. headquartered?
What is the Guardant360 LDT test used for?
How does Guardant Health contribute to early cancer detection?
